FDA reviews mental health reports linked to weight loss drugs semaglutide and tirzepatide.
The FDA is reviewing reports of anxiety, depression, and suicidal thoughts linked to the weight loss drugs semaglutide and tirzepatide, marketed as Wegovy and Zepbound. A study found no significant mental health score differences between users and non-users. The relationship between GLP-1 medications and mental health is complex, influenced by factors like blood sugar levels, nutrient intake, and lifestyle changes. Users are encouraged to consult healthcare providers about mood changes.
September 19, 2024
8 Articles